At the univariate per-lesion analysis, PET/CT indication (primary staging vs. restaging), prostate-specific antigen levels at the time of initial diagnosis and at the time of PET/CT, initial International Society of Urological Pathology grade group, ongoing androgen-deprivation therapy (ADT) at the time of PET/CT, the site of bone tracer uptake, SUVmax, total lesion PSMA, HUmean, and HUmax were associated with the presence of PCa metastases (Table 2). The gene discussed is FOLH1; the disease is posterior cortical atrophy.